Azathioprine metabolite measurements are not useful for following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people

Canadian Journal of Gastroenterology

Volumn 25, Issue 1, 2011, Pages 21-27

  Ferucci, Elizabeth D ^a   Hurlburt, Kathy J ^a   Mayo, Marlyn J ^b   Livingston, Stephen ^a   Deubner, Heike ^c   Gove, James ^a   Plotnik, Julia ^a   McMahon, Brian J ^a  

^a ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autoimmune liver disease; Azathioprine; Minority populations; Thiopurine methyltransferase

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; AZATHIOPRINE; DRUG METABOLITE; METHYLMERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MERCAPTOPURINE; METHYLTRANSFERASE;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BONE MARROW TOXICITY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PHENOTYPE; PRIORITY JOURNAL; REMISSION; ULCER; UNITED STATES; AMERICAN INDIAN; BLOOD; GENETIC ASSOCIATION; GENETICS; METABOLISM; MIDDLE AGED;

6-MERCAPTOPURINE; ADULT; ALASKA; AZATHIOPRINE; BIOLOGICAL MARKERS; FEMALE; GENETIC ASSOCIATION STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; INDIANS, NORTH AMERICAN; MALE; METHYLTRANSFERASES; MIDDLE AGED;

EID: 79952260306     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/137476     Document Type: Article

References (26)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54-66. (Pubitemid 43048951)
2. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97. (Pubitemid 34810370)
3. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63.
4. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13. (Pubitemid 34032538)
5. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62. (Pubitemid 10061685)
6. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14. (Pubitemid 27172187)
7. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30. (Pubitemid 30346978)
8. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18:395-400. (Pubitemid 37070237)
9. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis. Gastroenterology 2006;130:1047-53.
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13. (Pubitemid 30171620)
11. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37:441-7.
12. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-91. (Pubitemid 44307381)
13. Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2009;52:106-11.
14. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002;97:2402-7.
15. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38. (Pubitemid 29514229)
16. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76. (Pubitemid 351975541)
17. Luxon BA. Diagnosis and treatment of autoimmune hepatitis. Gastroenterol Clin North Am 2008;37:461-78. (Pubitemid 351680532)
18. Achkar JP, Stevens T, Easley K, Brzezinski A, Seidner D, Lashner B. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:339-45. (Pubitemid 39029175)
19. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009:CD000067.
20. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999;38:640-4. (Pubitemid 29507333)
21. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: Relation to azathioprine maintenance treatment and adverse effects. Ann Rheum Dis 2009;68:758-9.
22. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-8. (Pubitemid 38961966)
23. Hindorf U, Lyrenas E, Nilsson A, Schmiegelow K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1105-12. (Pubitemid 39536400)
24. Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: A preliminary report. J Pediatr Gastroenterol Nutr 2002;35:391-8.
25. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004;99:1744-8. (Pubitemid 39237503)
26. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73. (Pubitemid 27327100)